UBS analyst Nicholas Holowko downgraded Comerica (CMA) to Sell from Neutral with a price target of $64, up from $60, after assuming coverage of name. The firm sees below-Street pre-provision net revenue and “optionality” for Comerica. UBS says the rising tide of regulatory relief has the potential to lift multiples in the mid-cap bank space. But with the election “essentially unwinding the valuation hangover” from the 2023 regional bank crisis, “stock selection is crucial in 2025,” the analyst tells investors in a research note. UBS thinks the names to own in the current backdrop are those where outsized growth potential, capital optionality, and strategic value are not priced into shares today. Its outlook incorporates a Fed Funds rate of 4% by year-end 2025, and its earnings estimates are in-line with consensus over the next two years.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CMA:
- Comerica assumed with a Sell at UBS
- Comerica price target raised to $73 from $70 at JPMorgan
- Comerica price target raised to $80 from $64 at Compass Point
- Comerica sees Q4 NII in line with prior guidance of up 6%
- Comerica to Present at Goldman Sachs Conference
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
